Literature DB >> 21861667

Serum fatty acid profiling of colorectal cancer by gas chromatography/mass spectrometry.

Yasuyuki Kondo1, Shin Nishiumi, Masakazu Shinohara, Naoya Hatano, Atsuki Ikeda, Tomoo Yoshie, Takashi Kobayashi, Yuuki Shiomi, Yasuhiro Irino, Tadaomi Takenawa, Takeshi Azuma, Masaru Yoshida.   

Abstract

AIMS: Several screening methods have been applied for the early diagnosis of colorectal cancer, but most colorectal cancer patients are not diagnosed at a localized stage. In order to find novel biomarkers for the diagnosis of colorectal cancer, profiling of the serum levels of fatty acids, which are the main components of fats and are important factors for human metabolism, was performed using the sera of colorectal cancer patients. MATERIALS &
METHODS: A total of 42 colorectal cancer patients and eight healthy volunteers participated in this study. The serum levels of fatty acids, including free fatty acids and esterified fatty acids, were evaluated by gas chromatography/mass spectrometry. Then, partial least squares discriminant analysis was performed on the basis of the serum fatty acids detected by gas chromatography/mass spectrometry.
RESULTS: The serum levels of the nine fatty acids exhibited distinct differences between the colorectal cancer patients and healthy volunteers: the levels of four fatty acids were higher in the colorectal cancer patients than the healthy volunteers, and those of the other five fatty acids were lower. These changes were also observed at a very early clinical stage. Furthermore, the levels of very-long-chain fatty acids had a tendency to be increased in the sera of the colorectal cancer patients.
CONCLUSIONS: The pathogenesis of colorectal cancer leads to changes in the composition of serum fatty acids including free fatty acids and esterified fatty acids. These results suggest that serum fatty acid profiling may be used as a novel diagnostic tool for early-stage colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21861667     DOI: 10.2217/bmm.11.41

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  18 in total

Review 1.  Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography-mass spectrometry.

Authors:  Masaru Yoshida; Naoya Hatano; Shin Nishiumi; Yasuhiro Irino; Yoshihiro Izumi; Tadaomi Takenawa; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2011-11-02       Impact factor: 7.527

2.  Regulation of the metabolite profile by an APC gene mutation in colorectal cancer.

Authors:  Tomoo Yoshie; Shin Nishiumi; Yoshihiro Izumi; Aya Sakai; Jun Inoue; Takeshi Azuma; Masaru Yoshida
Journal:  Cancer Sci       Date:  2012-04-12       Impact factor: 6.716

Review 3.  Review of mass spectrometry-based metabolomics in cancer research.

Authors:  David B Liesenfeld; Nina Habermann; Robert W Owen; Augustin Scalbert; Cornelia M Ulrich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-04       Impact factor: 4.254

Review 4.  Novel methodologies in analysis of small molecule biomarkers and living cells.

Authors:  Yinan Chen; Zhenggang Zhu; Yingyan Yu
Journal:  Tumour Biol       Date:  2014-08-14

5.  Changes in urinary metabolic profiles of colorectal cancer patients enrolled in a prospective cohort study (ColoCare).

Authors:  David B Liesenfeld; Nina Habermann; Reka Toth; Robert W Owen; Eva Frei; Jürgen Staffa; Petra Schrotz-King; Karel D Klika; Cornelia M Ulrich
Journal:  Metabolomics       Date:  2014-12-20       Impact factor: 4.290

6.  Serum Unsaturated Free Fatty Acids: A Potential Biomarker Panel for Early-Stage Detection of Colorectal Cancer.

Authors:  Yaping Zhang; Chengyan He; Ling Qiu; Yanmin Wang; Xuzhen Qin; Yujie Liu; Zhili Li
Journal:  J Cancer       Date:  2016-01-29       Impact factor: 4.207

Review 7.  Metabolomics for the masses: The future of metabolomics in a personalized world.

Authors:  Drupad K Trivedi; Katherine A Hollywood; Royston Goodacre
Journal:  New Horiz Transl Med       Date:  2017-03

8.  Serum metabolomic profile as a means to distinguish stage of colorectal cancer.

Authors:  Farshad Farshidfar; Aalim M Weljie; Karen Kopciuk; W Don Buie; Anthony Maclean; Elijah Dixon; Francis R Sutherland; Andrea Molckovsky; Hans J Vogel; Oliver F Bathe
Journal:  Genome Med       Date:  2012-05-14       Impact factor: 11.117

9.  From genotype to functional phenotype: unraveling the metabolomic features of colorectal cancer.

Authors:  Oliver F Bathe; Farshad Farshidfar
Journal:  Genes (Basel)       Date:  2014-07-22       Impact factor: 4.096

10.  Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.

Authors:  Sebastian May-Wilson; Amit Sud; Philip J Law; Kimmo Palin; Sari Tuupanen; Alexandra Gylfe; Ulrika A Hänninen; Tatiana Cajuso; Tomas Tanskanen; Johanna Kondelin; Eevi Kaasinen; Antti-Pekka Sarin; Johan G Eriksson; Harri Rissanen; Paul Knekt; Eero Pukkala; Pekka Jousilahti; Veikko Salomaa; Samuli Ripatti; Aarno Palotie; Laura Renkonen-Sinisalo; Anna Lepistö; Jan Böhm; Jukka-Pekka Mecklin; Nada A Al-Tassan; Claire Palles; Susan M Farrington; Maria N Timofeeva; Brian F Meyer; Salma M Wakil; Harry Campbell; Christopher G Smith; Shelley Idziaszczyk; Timothy S Maughan; David Fisher; Rachel Kerr; David Kerr; Michael N Passarelli; Jane C Figueiredo; Daniel D Buchanan; Aung K Win; John L Hopper; Mark A Jenkins; Noralane M Lindor; Polly A Newcomb; Steven Gallinger; David Conti; Fred Schumacher; Graham Casey; Lauri A Aaltonen; Jeremy P Cheadle; Ian P Tomlinson; Malcolm G Dunlop; Richard S Houlston
Journal:  Eur J Cancer       Date:  2017-08-19       Impact factor: 10.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.